After Launching First Pegylated GCSF, Intas Biopharma Examines Technology For Pegylated Erythropoietin
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Ahmedabad, India-based biotech firm Intas Biopharma is looking at commencing research on a generic form of pegylated erythropoietin
You may also be interested in...
With Plans For Public Offerings, Emcure, Intas Set To Join Big League Of Indian Pharma
Experts believe Emcure and Intas may be able to withstand the vagaries of India’s choppy financial market, having developed strong pedigrees of products and consistently growing their businesses.
India's Dr. Reddy's Is Set To Launch A Fourth Biosimilar - Pegfilgrastim
With filgrastim, rituximab and darbepoetin alfa already under its belt, Dr. Reddy's says it has seven more products - the bulk of which are thought to be copies of established monoclonal antibodies - in early development and preclinical testing.
India's Dr. Reddy's Is Set To Launch A Fourth Biosimilar - Pegfilgrastim
With filgrastim, rituximab and darbepoetin alfa already under its belt, Dr. Reddy's says it has seven more products - the bulk of which are thought to be copies of established monoclonal antibodies - in early development and preclinical testing.